Once-in-a-lifetime screening for Barrett esophagus has been proposed for patients with gastroesophageal reflux disease (GERD), but there is little evidence of its cost-effectiveness. 1] To determine the cost-effectiveness of screening high-risk groups for Barrett esophagus and providing surveillance to patients with Barrett esophagus and dysplasia or to all patients with Barrett esophagus and 2) to compare the results with the cost-effectiveness of no screening or surveillance. A decision analytic model was developed to examine no screening or surveillance and screening and surveillance for Barrett esophagus with dysplasia only or Barrett esophagus without dysplasia every 2 to 5 years. Low- or high-grade dysplasia received surveillance every 6 or 3 months, respectively. Published literature and the Health Care Financing Administration. 50-year-old white men with symptoms of GERD. 50 years of age until 80 years of age or death. Third-party payer. Incremental cost-effectiveness ratio. Screening with surveillance limited to patients with Barrett esophagus with dysplasia required $10 440 per quality-adjusted life-year (QALY) saved compared to no screening or surveillance. The incremental cost-effectiveness ratio of surveillance every 5 years in patients with Barrett esophagus without dysplasia compared to surveillance of patients with Barrett esophagus with dysplasia was $596 000 per QALY saved. The annual incidence of adenocarcinoma must exceed 1 case per 54 patient-years of follow-up (1.9%) for surveillance of Barrett esophagus without dysplasia every 5 years to yield an incremental cost-effectiveness ratio less than $50 000 per QALY saved. Screening 50-year-old men with symptoms of GERD to detect adenocarcinoma associated with Barrett esophagus is probably cost-effective. However, subsequent surveillance of patients with Barrett esophagus but no dysplasia, even at 5-year intervals, is an expensive practice.
Background & Aims: Alarm features such as dysphagia, weight loss, or anemia raise concern of an upper gastrointestinal malignancy in patients with dyspepsia. The aim of this study was to determine the diagnostic accuracy of alarm features in predicting malignancy by performing a metaanalysis based on the published literature. Methods: English-language studies were identified by searching MEDLINE, EMBASE, Cochrane Controlled Trials Register, and CINAHL. Cohort studies that measured alarm features and compared them with the endoscopic findings were included. Studies were screened for inclusion by 2 authors who independently extracted the data. Sensitivity, specificity, and likelihood ratios were calculated by comparing the alarm feature with the endoscopic diagnosis. The summary receiver operating characteristic curve method was used to summarize test characteristics across studies. Individual alarm features were also assessed when the study report permitted. Results: Eighty-three of 2600 studies met the initial screening criteria; 15 met inclusion criteria after detailed review. These 15 studies evaluated a total of 57,363 patients, of whom 458 (.8%) had cancer. The sensitivity of alarm symptoms varied from 0% to 83% with considerable heterogeneity between studies. The specificity also varied significantly from 40% to 98%. A clinical diagnosis made by a physician was very specific (range, 97%–98%) but not very sensitive (range, 11%–53%). Conclusions: Alarm features have limited predictive value for an underlying malignancy. Their use in dyspepsia management strategies needs further refinement and study.
Background : The ideal duration of Helicobacter pylori treatment in the United States and whether eradication therapy is as successful in nonulcer dyspepsia as in peptic ulcer disease are controversial topics. Aim : This study compared the efficacy of 3‐, 7‐ and 10‐day triple therapies with rabeprazole to a 10‐day omeprazole control triple therapy for the eradication of Helicobacter pylori in patients with and without peptic ulcer disease in the United States. Methods : This was a multicentre, double‐blind, randomized, parallel‐group trial. A total of 803 patients with H. pylori infection (determined by [13C]urea breath test and rapid urease test or culture) received either rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., and clarithromycin 500 mg b.d. for 3, 7, or 10 days, or 10 days of omeprazole 20 mg b.d. with the same antibiotic regimen (control). H. pylori status was assessed by [13C]urea breath test ≥6 weeks after completing treatment. Results : In intent‐to‐treat patients, the eradication percentages achieved for the rabeprazole‐based treatments were: 3‐day, 27% (95% confidence interval: 21%–34%); 7‐day, 77% (95% confidence interval: 71%–83%); and 10‐day, 78% (95% confidence interval: 72%–84%). The eradication percentage with the 10‐day omeprazole‐based treatment was 73% (95% confidence interval: 67%–79%). There was no statistically significant difference between the 7‐day rabeprazole‐based regimen and the 10‐day rabeprazole‐ and omeprazole‐based regimens. Conclusions : Seven‐day therapy with rabeprazole, clarithromycin, and amoxicillin is similar in efficacy to 10‐day therapies and had similar efficacy in patients with and without ulcer disease.
1 August 2004 in Clinical Gastroenterology and Hepatology
Summary: Background: Many investigators have proposed an association between gastro‐oesophageal reflux disease and laryngo‐pharyngeal symptoms, suggesting that medical or surgical therapy for reflux may be useful.Aim: To perform a meta‐analysis assessing the effectiveness of medical or surgical therapy for reflux disease in adult patients with laryngeal or pharyngeal symptoms presumed to be due to gastro‐oesophageal reflux disease.Methods: Randomized controlled trials comparing medical or surgical treatments for gastro‐oesophageal reflux disease against placebo were identified by searching MEDLINE (1966–September 2005), EMBASE (1974–September 2005), the CCRCT (until September 2005) and abstracts from gastroenterology and ENT meetings. The relative risks of reporting symptomatic improvement or resolution of symptoms was evaluated using a random‐effects model.Results: Five studies using high‐dose proton pump inhibitor as intervention met the inclusion criteria and were included in the meta‐analysis. No surgical studies met inclusion criteria. The pooled relative risk was 1.18 (95% confidence interval: 0.81–1.74). There was no heterogeneity between studies but evidence of significant publication bias. Sub‐group analysis performed evaluating Jadad scores and symptom type, did not change the relative risk.Conclusions: Therapy with a high‐dose proton pump inhibitor is no more effective than placebo in producing symptomatic improvement or resolution of laryngo‐pharyngeal symptoms. Further studies are necessary to identify the characteristics of patients that may respond to proton pump inhibitor therapy.